Nrx pharmaceuticals, inc. (nasdaq: nrxp) reports comments by strategic partner lotus pharmaceutical co. ltd. (1975.tw) in recent financial report

Companies continue to work collaboratively to advance nrx-101 in bipolar depression with suicidality lotus notes that nrx has "achieved a significant milestone by completing enrollment for its phase 2b/3 trial of nrx-101 in suicidal treatment-resistant bipolar depression. the readout for this trial is anticipated in q2 of this year.
NRXP Ratings Summary
NRXP Quant Ranking